ClinicalTrials.gg
CompletedNCT02028767Updated Jul 24, 2015Results posted

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

A Phase 1 interventional study of Empagliflozin 2.5 mg and Empagliflozin 10 mg in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Canada. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-07-24.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The trial is being conducted to establish the bioequivalence of emp/met (12.5mg/500mg) fixed dose combination tablets compared to tablets administered together in healthy male and female volunteers under fed conditions.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males or females according to the investigator's assessment, as based on the following criteria: a complete medical history including a physical examination, vital signs (BP, PR), 12-lead and clinical laboratory tests.
  2. Age 18 to 50 years (inclusive)
  3. 18.5 to 29.9 kg/m2 (inclusive)
  4. Signed and dated written prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation.

Exclusion criteria

Exclusion criteria:

  1. Any finding in the medical examination (Including blood pressure [BP], pulse rate [PR], or [ECG]) deviating from normal and judged by the investigator.
  2. Any evidence of a concomitant disease judged clinically relevant by the investigator.
  3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.
  4. Surgery of the gastrointestinal tract that could interfere with kinetics of the study drug(s)
  5. Diseases of the central nervous system (such as epilepsy), other neurological disorders or psychiatric disorders.
  6. History of relevant orthostatic hypotension, fainting spells, or blackouts.
  7. Chronic or relevant acute infections
  8. History of relevant allergy/ (including allergy to the trial medication or it's )
  9. Intake of drugs with a long half-life (>24 hours) within 30 days or less than 10 half-lives of the respective drug prior to administration of trial medication.
  10. Within 14 days prior to the administration of trial medication, use of drugs that might reasonably influence the results of the trial, based on current knowledge
  11. Participation in another trial with drug administration within 60 days prior to administration of trial medication.
  12. Smoker (has used tobacco or nicotine-containing products within 6 months prior to administration of trial medication)
  13. Inability to refrain from smoking on specified trial days
  14. Alcohol abuse (consumption of more than 20g/day in females and 30g/day in males or > 7 alcohol-containing drinks per week)
  15. Drug abuse or positive drug screen
  16. Blood donation (more than 100 ml wihtin 30 days prior to administration of trial medication or intended during the trial)
  17. Intention to perform excessive physical activities within one week prior to administration of trial medication or during the trial
  18. Inability to comply with dietary regimen of trial site
  19. Subject is assessed by the investigator as unsuitable for inclusion, for instance, because considered not able to understand and comply with study requirements, or has a condition that would not allow safe participation in the study.

    For female subjects:

  20. Positive pregnancy test, pregnancy or plans to become pregnant within 30 days after study completion.
  21. No adequate during the study and until 1 month after study completion, i.e. not any of the following: implants, injectables, combined oral contraceptives, IUD (intrauterine device), sexual abstinence for at least 1 month prior to enrolment, vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilisation (including hysterectomy). Females, who do not have a vasectomised partner, are not sexually abstinent, surgically sterile, or post menopausal will be asked to use an additional barrier method (e.g. condom, diaphragm with spermicide). is defined as at least 1 year of spontaneous amenorrhea and deemed post menopausal by a physician based on screening clinical laboratory tests (follicle stimulating hormone and luteinizing hormone).
  22. Lactation
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Fixed Dose Combination (FDC)

    12.5 mg Empagliflozin / 500mg metformin fixed dose combination

    Drug: Empagliflozin/Metformin FDC

  • Active comparator
    Separate tablets

    Empagliflozin and Metformin tablets

    Drug: Empagliflozin 2.5 mg · Drug: Empagliflozin 10 mg · Drug: Metformin 500 mg

Interventions

06

What researchers measure

Primary outcomes

  1. AUC (0-tz) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point)

    AUC (0-tz) (area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point)

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

  2. Cmax (Maximum Measured Concentration of Metformin in Plasma)

    Cmax (maximum measured concentration of metformin in plasma)

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

Secondary outcomes

  1. AUC (0-infinity) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)

    AUC (0-infinity) (Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity)

    Time frame: 1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration

07

Results

Posted Jul 24, 2015

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneFixed Dose Combination (FDC) First, Then Separate TabletsSeparate Tablets First, Then Fixed Dose Combination (FDC)
Started1616
Completed1616
Not completed00
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneFixed Dose Combination (FDC) First, Then Separate TabletsSeparate Tablets First, Then Fixed Dose Combination (FDC)
Started1616
Completed1416
Not completed20
Withdrew: Non compliant with protocol10
Withdrew: Reason other than those specified above10

Outcome measures

PrimaryAUC (0-tz) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point)

AUC (0-tz) (area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point)

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng*h/mL
AUC (0-tz) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point)
ng*h/mLFixed Dose Combination (FDC)Separate Tablets
AUC (0-tz) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point)6260 ± 20.46360 ± 21.8
Statistical analysis
  • Fixed Dose Combination (FDC) vs Separate Tablets · ANOVA · p = 0.0000 (The p-value relates to the null hypothesis of non-equivalence.) · Geometric mean ratio: 98.57 · 90% CI 94.662 to 102.639The geometric mean ratio is the exponential of the estimated mean difference on the log-scale between 'FDC' and 'Separate tablets'. ANOVA on the log scale: sequence, period and treatment as fixed effects; subjects within sequences as random effect
  • Fixed Dose Combination (FDC) vs Separate Tablets · ANOVA · p = <0.0001 (The p-value relates to the null hypothesis of non-equivalence.) · Geometric mean ratio: 98.71 · 90% CI 94.783 to 102.796The geometric mean ratio is the exponential of the estimated mean difference on the log-scale between 'FDC' and 'Separate tablets'. ANOVA on the log-scale: sequence, subjects within sequences, period and treatment as fixed effects
PrimaryCmax (Maximum Measured Concentration of Metformin in Plasma)

Cmax (maximum measured concentration of metformin in plasma)

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng/mL
Cmax (Maximum Measured Concentration of Metformin in Plasma)
ng/mLFixed Dose Combination (FDC)Separate Tablets
Cmax (Maximum Measured Concentration of Metformin in Plasma)746 ± 21.3754 ± 23.3
Statistical analysis
  • Fixed Dose Combination (FDC) vs Separate Tablets · ANOVA · p = 0.0000 (The p-value relates to the null hypothesis of non-equivalence.) · Geometric mean ratio: 98.93 · 90% CI 95.856 to 102.107The geometric mean ratio is the exponential of the estimated mean difference on the log-scale between 'FDC' and 'Separate tablets'. ANOVA on the log-scale: sequence, period and treatment as fixed effects; subjects within sequences as random effect
  • Fixed Dose Combination (FDC) vs Separate Tablets · ANOVA · p = <0.0001 (The p-value relates to the null hypothesis of non-equivalence.) · Geometric mean ratio: 98.96 · 90% CI 95.877 to 102.150The geometric mean ratio is the exponential of the estimated mean difference on the log-scale between 'FDC' and 'Separate tablets'. ANOVA on the log-scale: sequence, subjects within sequences, period and treatment as fixed effects
SecondaryAUC (0-infinity) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)

AUC (0-infinity) (Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity)

Time frame:
1 hour (h) before drug administration and 20 minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 34h, 48h and 72h after drug administration
Reported as:
Geometric mean · ng*h/mL
AUC (0-infinity) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)
ng*h/mLFixed Dose Combination (FDC)Separate Tablets
AUC (0-infinity) (Area Under the Concentration-time Curve of Metformin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)6410 ± 20.96520 ± 22.5
Statistical analysis
  • Fixed Dose Combination (FDC) vs Separate Tablets · ANOVA · p = 0.0000 (The p-value relates to the null hypothesis of non-equivalence.) · Geometric mean ratio: 98.28 · 90% CI 94.549 to 102.156The geometric mean ratio is the exponential of the estimated mean difference on the log-scale between 'FDC' and 'Separate tablets'. ANOVA on the log-scale: sequence, period and treatment as fixed effects; subjects within sequences as random effect
  • Fixed Dose Combination (FDC) vs Separate Tablets · ANOVA · p = <0.0001 · Geometric mean ratio: 98.35 · 90% CI 94.603 to 102.252The geometric mean ratio is the exponential of the estimated mean difference on the log-scale between 'FDC' and 'Separate tablets'. ANOVA on the log-scale: sequence, subjects within sequences, period and treatment as fixed effects

Adverse events

Collected over From first trial medication intake until next intake or the day after the end-of-trial visit, 16 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fixed Dose Combination (FDC)—0/32 (0%)11/32 (34.4%)
Separate Tablets—0/30 (0%)5/30 (16.7%)
Most frequent other events
Most frequent other events
EventFixed Dose Combination (FDC)Separate Tablets
SomnolenceNervous system disorders7/324/30
HeadacheNervous system disorders4/321/30
VomitingGastrointestinal disorders2/320/30

Baseline characteristics

Treated set (TS): includes all subjects who were dispensed study medication and were documented to have received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(years)Fixed Dose Combination vs. Separate Tablets
Mean36.1 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Fixed Dose Combination vs. Separate Tablets
Female13
Male19
08

Study locations

1 site
  • 1276.24.001 Boehringer Ingelheim Investigational Site
    Toronto, Ontario, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2014
First posted
Jan 7, 2014
Start
Jan 2014
Primary completionActual
Feb 2014
CompletionActual
Feb 2014
Results first posted
Jul 24, 2015
Last update
Jul 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02028767
Responsible party
Sponsor
First posted
Jan 7, 2014
Start date
Jan 2014
Primary completion
Feb 2014
Completion
Feb 2014
Results posted
Jul 24, 2015
Last update
Jul 24, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Metformin

Start the discussion